首页> Journal of clinical oncology : official journal of the American Society of Clinical Oncology> Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.

导出 OA

翻译打印收藏纠错

第一作者： Giovanni,Scambia

第一单位： Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy.

作者： Giovanni,Scambia ^[1] ; Ricardo,Villalobos Valencia ^[2] ; Nicoletta,Colombo ^[3] ; David,Cibula ^[4] ; Charles A,Leath ^[5] ; Mariusz,Bidziński ^[6] ; Jae-Weon,Kim ^[7] ; Joo Hyun,Nam ^[8] ; Radoslaw,Madry ^[9] ; Carlos,Hernández ^[10] ; Paulo A R,Mora ^[11] ; Sang Young,Ryu ^[12] ; Mei-Lin,Ah-See ^[13] ; Elizabeth S,Lowe ^[14] ; Natalia,Lukashchuk ^[15] ; Dave,Carter ^[16] ; Richard T,Penson ^[17]

作者单位： Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy. ^[1] Centro Medico Dalinde, Mexico City, Mexico. ^[2] Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.;Gynecologic Oncology Program European Institute of Oncology IRCCS, Milan, Italy. ^[3] Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. ^[4] O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, AL. ^[5] Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. ^[6] Seoul National University Hospital, Seoul, South Korea. ^[7] Asan Medical Center, Seoul, South Korea. ^[8] Poznan University of Medical Sciences, Poznań, Poland. ^[9] Oaxaca Site Management Organization, Oaxaca de Juarez, Mexico. ^[10] Instituto COI de Educação e Pesquisa, Rio de Janeiro, Brazil. ^[11] Korea Institute of Radiological and Medical Sciences, Seoul, South Korea. ^[12] Oncology R&D, Late-stage Development, AstraZeneca, Cambridge, United Kingdom. ^[13] Oncology R&D, Late-stage Development, AstraZeneca, Gaithersburg, MD. ^[14] Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. ^[15] Biostatistics, Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. ^[16] Harvard Medical School, Massachusetts General Hospital, Boston, MA. ^[17]